Full-Time

Business Intelligence – Lead

BI

Posted on 6/20/2026

Deadline 6/22/26
Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Hyderabad, Telangana, India + 1 more

More locations: Chennai, Tamil Nadu, India

In Person

Category
Data & Analytics (1)
Required Skills
Figma
SQL
Tableau
Data Governance
Requirements
  • Hold a Bachelor's or Master's Degree in Computer Science, Engineering or other technical disciplines and 7+ years of experience in Business Intelligence with a progressive shift from hands-on development to leading delivery and stakeholder engagement.
  • Strong foundation in Tableau development, dashboarding, data modeling and reporting techniques, with the ability to guide and review the work of others.
  • A consultative mindset, with the ability to assess feasibility, identify data challenges, and proactively suggest improvements in how data is used, visualized, or measured.
  • Experience in developing and overseeing BI solutions supporting sales performance reporting.
  • Experience in optimizing dashboards with a focus on usability, performance, flexibility and standardization.
  • Experience in data modeling, data cleansing and data transformation activities.
  • Experience in end-to-end implementation of BI projects for developing a portfolio of scorecards, KPIs, reports & dashboards.
  • Experience in writing and debugging SQL queries.
  • Strong communication skills with the confidence to lead discussions and articulate technical constraints to business audiences.
  • Experience guiding or mentoring a team of BI developers.
  • Prior experience or knowledge of pharmaceuticals or healthcare industry landscape is an added advantage.
Responsibilities
  • Serve as the primary point of contact for business leaders to gather requirements, manage expectations, and provide transparent project timelines across multiple workstreams
  • Assess and recommend the right BI approach for a given problem, considering data availability, platform capabilities, and business context, and communicate trade-offs clearly to non-technical audiences
  • Drive the design and delivery of enterprise-grade BI applications (Tableau), ensuring scalability, performance, security and data governance
  • Lead data discovery sessions to identify new data sources and ensure the underlying data warehouse architecture supports long-term BI reporting needs
  • Guide the translation of business requirements into analytics prototypes that provide meaningful business and data insights
  • Oversee data and BI analysis efforts, including review of source systems, KPI definitions and aggregations, ensuring quality and consistency
  • Review and guide the development of Tableau applications, ensuring reporting components from multiple data sources are integrated effectively
  • Create and understand Figma-based prototypes to understand the "user journey" of data. Translate these designs into functional KPIs for BI developers
  • Provide oversight of the end to end BI ecosystem (Desktop, Server, and Cloud), ensuring best practices in dashboard performance, security and scalability
  • Mentor and guide team members, fostering a collaborative environment and contributing to overall team growth

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Your Connections

People at Roche who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VENTANA PTEN RxDx creates a new prostate cancer companion-diagnostic revenue stream.
  • PathAI acquisition expands AI-driven diagnostics and global digital pathology workflow integration.
  • Nurix collaboration extends Roche into BTK degraders across hematology and immunology.

What critics are saying

  • Swiss franc strength continues depressing reported earnings from Roche’s Swiss cost base.
  • Upcoming patent expirations threaten legacy pharmaceutical revenue before new launches mature.
  • Obesity competition from Novo Nordisk and Eli Lilly leaves CT-388 behind.

What makes Roche unique

  • Roche unites pharmaceuticals, diagnostics, and digital pathology across healthcare workflows.
  • Founded in Basel in 1896, Roche built scale through branded medicines.
  • Genentech acquisition made Roche the world’s largest biotechnology company.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE